The Cover Story
Featured Company · #01NurExone Biologic Inc.
NurExone is building a first-in-class, non-cell-based exosome platform aimed at two conditions with no restorative therapy today — traumatic spinal cord injury and optic-nerve / glaucoma damage. Its lead asset carries dual FDA and EMA orphan-drug designations, and a first regulatory catalyst is on the near-term horizon.
The company's ExoTherapy platform harvests nanoscale exosomes from mesenchymal stem cells and loads them with a therapeutic siRNA cargo — turning the body's own delivery vehicles into biologically guided nanocarriers that home to damaged neural tissue, including via a minimally invasive intranasal route.
Its flagship, ExoPTEN, silences PTEN — a molecular brake on nerve regeneration — to switch the body's own repair response back on at the injury site. In preclinical spinal-cord models, intranasal ExoPTEN recovered motor function in roughly 75% of treated animals; in a glaucoma model it produced reproducible, dose-dependent vision recovery and retinal-cell preservation.
Both indications are sizeable: acute SCI sees an estimated ~900,000 new cases a year (lifetime care often >US$1M/patient) and acute glaucoma 350,000–700,000 — each framed as a multi-billion-dollar market with no restorative option today.
Beyond the two lead programs, NurExone adds optionality: a chronic-SCI collaboration with Inteligex, potential non-dilutive revenue from US subsidiary Exo-Top (naïve-exosome sales, targeted H1 2026), and a team whose founders helped build Pluristem, BrainStorm, and Gamida Cell. It is now assembling the pieces for its preclinical-to-clinical transition — the inflection that historically re-rates names in this space.
Pipeline · Lead Programs
Why it leads our list: Among these four, NurExone is the earliest-stage and lowest-priced — and that's the point. It is the only name pairing an exosome-plus-siRNA platform against two high-unmet-need CNS indications, backed by dual orphan designations and a definable 2026 IND catalyst. The trade-off is real: no human data yet, and micro-cap financing risk. This is an early, speculative, catalyst-driven story — sized accordingly.